And while we are not in a position, given that we organized our publicly traded companies, right? We’re not in a position to share the specifics around all the activities they’re doing and all the details on what the objectives are. What we can do is give you a little more perspective on just your question specifically around step edits because that’s something really important to understand that is very unique about this category compared to other categories. We’re step-editing even if it was required is not as big of an impediment as it might be another category because of how recurrent bacterial vaginosis is and the fact that many of these women will have already been through that. So John, if you can maybe just talk a little bit about the recurrence rate of bacterial vaginosis and how common it is for women who have already been on a treatment in the prior period?
And what that means having already stepped through products.
John Fair: Yes, we’ll do. Thank you, Sabrina. Yes. And I think just taking a step back, so bacterial vaginosis, it’s not a very heavily managed category. It’s not a big budget hit for a lot of health plan. So there’s not a lot of utilization management happening in there already. But in terms of your direct question, in about 50% of all cases women are going to recur. And recurrent bacterial vaginosis is essentially 3 or more episodes in a given year. When a step edit is applied, it’s generally when she needs to graduate through something to get to something. And in our situation and again, we believe this to be the case, we’re not speaking for anybody else, there are going to be a number of women who will automatically sort of stepped through a previous therapy.
So that step — if there’s a step edit which not clear that there will be because, again, the category is not managed that tightly. But if there is, it’s very likely that a big portion of the population will already “step through” and should have access to the brand.
Operator: Your next question comes from the line of Jason McCarthy from Maxim Group.
Joanne Lee: This is Joanne Lee, on the call for Jason McCarthy. Congratulations on all the progress. So a lot of questions were asked around the Sildenafil program but I wanted to ask about the HRT1 program as well, for which we saw the positive efficacy data in Q4 and this was followed by the safety and PK outcomes earlier this year. And now the company you guys are positioned to file the Phase III IND. Can you briefly, just as a reminder, walk us through some of the key data that has emerged from the Phase I/II as well as other factors, including maybe the unmet need in the space that may have attributed to the decision to progress that drug straight into the Phase III program? And as a follow-up, what are the expectations in terms of the time lines around the IND submission and the study initiation?
Sabrina Johnson: Great. Thank you for — first of all, thank you again for the kind words and thank you for asking about that product. It is definitely one that we’re quite passionate about at the company for some of the reasons that you cited. So first of all, taking a step back and I mentioned this briefly into my comments but the North American Menopause Society, by the way, a little commercial for anyone looking for information about menopause, they are a great reputable source of information. These are the clinicians that have very much taken on menopause share, right, as something that’s important to them and they’ve really studied menopause and studied what happens during menopause and what are the needs that women have during menopause.
